Tyra Biosciences Q4 2022 Earnings Report

Tyra Biosciences EPS Results

• Actual EPS: -$0.31
• Consensus EPS: -$0.35
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: N/A

Tyra Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tyra Biosciences Announcement Details

• Quarter: Q4 2022
• Date: 3/22/2023
• Time: N/A

Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.